ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / AGL / dividends
PGNY (79) SHC (49) VMD (72) DVA (74) ⌘ Pro Terminal β†’

agilon health inc. (AGL) Dividend Safety Gauge & 10-Year DRIP Compounder

$84.90 -1.21% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $84.55

agilon health inc. (AGL) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D- β€’ RED ALERT Cap $1.43B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AGL Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is AGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, agilon health inc. (NYSE: AGL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $84.90 (-1.21% 1D, market cap $1.43B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AGL ranks #561 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does AGL compare to PGNY and SHC in the Health Care sector?
β–Ό

Within the Health Care sector (Misc Health and Biotechnology Services), AGL carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, PGNY (Progyny Inc.) holds a B+ grade (79/100 RQD, P/E 37.2x, ROIC 16.7%, cap $2.24B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AGL?
β–Ό

Per AGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831097), agilon health inc. generated $5.93B in revenue (-2.1% YoY), -$391.3M in net income, and -$119.0M in free cash flow against $1.27B in total assets and $15.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $84.55 (-0.41%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (5)Whales (9)SEC (7)Macro (12)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$140 Bull$76 Base$60 Bear
πŸ“¬ FREE AGL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for AGL)Realized 20D OHLCV Swing Band: Β±11.2%
Deterministic 5-Pillar Attribution (36/100 Composite)
πŸ” WHY AGL SCORES 36/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+12/20 pts (33% of score)

FRED Regime Γ— Technicals: 62% of 52W Range β€’ RSI-14 at 44.4 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)

20D Institutional Volume Accumulation (Β±11.2% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
44
Grade D$85.90+6.8% Next Q
Q2 (-2Q)
41
Grade D$91.72-1.2% Next Q
Q3 (-1Q)
39
Grade E$90.65-6.3% Next Q
Current
36
Grade D-$84.90-8.3% Hist 90D Ξ±
Trajectory: D (44) β†’ D- (36)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a AGL Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While AGL currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($87.48) and Max Pain ($89.15) forces dealer call-delta covering toward $139.69.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AGLβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AGL)

  • βœ“Walkthrough of AGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
AGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +215.14%⚑ TESTING RESISTANCE
2026-11-03O $85.94H $85.94L $84.90C $84.90VOL 217.5K
RES: $90.61SUP: $59.34SMA50: $87.48SMA200: $65.59
$141.1$107.7$74.29$40.88$7.47RES $90.61SUP $59.34$84.902026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ AGL Butterfly Map β†’ + Track AGL β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -2.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AGL today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for AGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AGL)

Health Care Rank #561 of 1016 βš”οΈ PGNY vs AGL Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (AGL vs. PGNY, SHC, VMD, DVA)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, agilon health inc. (AGL) ranks #561 by composite RQD confidence (36/100, grade D-) and #309 by equity capitalization ($1.43B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and β€” gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with AGL at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AGL ACTIVE
agilon health inc.
D- 36/100 β€” β€” -35.0% -1.21% $1.43B Benchmark Subject
PGNY
Progyny Inc.
B+ 79/100 37.2x 23.6% 16.7% +2.78% $2.24B /pgny-vs-agl β†’
SHC
Sotera Health Company
D 49/100 68.5x 55.5% 3.1% -2.94% $5.18B /shc-vs-agl β†’
VMD
Viemed Healthcare Inc.
B 72/100 24.6x 57.5% 13.0% -2.81% $368.3M /vmd-vs-agl β†’
DVA
DaVita Inc.
B 74/100 11.4x β€” 29.2% -3.01% $11.79B /dva-vs-agl β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001831097

In its most recent audited fiscal period (FY2025, filed 2025-12-31), agilon health inc. (AGL) reported GAAP revenue of $5.93B (-2.1% vs. FY2024 revenue of $6.06B , and +37.4% cumulative change since FY2023) , GAAP net income of -$391.3M, operating cash flow of -$105.8M, and free cash flow of -$119.0M (-67.5% YoY). On the balance sheet, AGL closed FY2025 with $1.27B in total assets against $15.8M in total debt (Altman Z-Score: 2.06, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $5.93B -$391.3M -$105.8M -$119.0M $1.27B $15.8M
FY2024 (FY) 2024-12-31 $6.06B -$260.2M -$57.8M -$71.0M $1.73B $34.9M
FY2023 (FY) 2023-12-31 $4.32B -$262.6M -$156.2M -$156.2M β€” β€”

3. AGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, agilon health inc. (NYSE: AGL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $84.90 (-1.21% 1D, market cap $1.43B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AGL ranks #561 in composite RQD confidence.

How does AGL compare to PGNY and SHC in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), AGL carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, PGNY (Progyny Inc.) holds a B+ grade (79/100 RQD, P/E 37.2x, ROIC 16.7%, cap $2.24B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AGL?

Per AGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831097), agilon health inc. generated $5.93B in revenue (-2.1% YoY), -$391.3M in net income, and -$119.0M in free cash flow against $1.27B in total assets and $15.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AGL trading relative to its 50-day, 200-day, and 52-week technical levels?

AGL last traded at $84.90 (-1.21% on volume of 217,489 shares), positioning the stock -2.95% below its 50-day simple moving average ($87.48) and +29.44% above its 200-day simple moving average ($65.59). Across its 52-week range of $7.48 to $133.04, AGL sits at the 61.7% percentile with a 14-day RSI of 44.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.2% ($75.39 to $94.41).

AGL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Does AGL pay a dividend and is it safe?

agilon health inc. (AGL) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: AGL RQD Cockpit AGL 12M Forecast AGL Earnings & Move AGL Dividends & DRIP AGL Insiders & 13F AGL Whale Options AGL Profit Sankey AGL News & Why
ROARABLE RATING BRIEF β€’ RQD 36/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

AGL β€” agilon health inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:29:08Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns AGL a score of 37 out of 100 and a letter grade of D-, with the verdict label "Roarable Sell β€” Vulnerable Balance Sheet & Flow," per the Roarable RQD rating.

  • Fundamental Cash Engine (5 / 20): Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -8.25%. For a prospective investor, the weakest pillar in the framework signals that the business is not currently converting capital into cash returns; valuation support from cash generation is absent.
  • Whale 13F Flow (10 / 20): Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning and scored 10 of 20. The source does not provide 13F holder detail, so the basis for this score cannot be independently traced in this brief.
  • Insider Conviction (3 / 20): Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow and scored 3 of 20, the lowest of the five. For a prospective investor this is a notable caution signal, though the underlying transactions are not itemized in the source.
  • Macro Regime Fit (12 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity, scoring 12 of 20. A beta of 1.0 indicates market-level volatility exposure, neither defensive nor amplified.
  • Forensic Balance Sheet (7 / 20): Per the Roarable RQD rating, the Altman Z-Score is 2.06, the Piotroski F-Score is 3/9, and Debt/Equity is 0.12. Debt is low relative to equity, which is a mitigating factor, but the Piotroski reading is weak and the Z-Score sits in a range that warrants scrutiny.

Taken together, the score profile suggests that the upside case depends on a turnaround in operating economics, since the cash engine and insider flow pillars are the weakest. The valuation tradeoff is that the stock's price action (see Snapshot) has been extreme over the past year, so any investor evaluating the name today is weighing a very wide historical range against deteriorating fundamentals.

Business

agilon health inc. is a NYSE-listed company in the Health Care sector, operating within the Misc Health and Biotechnology Services industry, per the profile. The company's product offering, customer base, and revenue model are not described in the source data beyond its sector classification. Per the SEC financials, FY 2025 revenue was $5932.6M, indicating a substantial revenue base despite operating losses.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$5932.6M$-463.2M$-391.3MN/A$-119.0M$173.7M$15.8M
FY 2024$6060.5M$-292.1M$-260.2MN/A$-71.0M$188.2M$34.9M
FY 2023$4316.4M$-232.1M$-262.6MN/A$-156.2MN/AN/A

Per the SEC financials, the company reported operating and net losses in each listed period, with the FY 2025 operating loss widening to $-463.2M. Per the market data, the operating margin is -7.8%, net margin is -6.6%, gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.06 and the Piotroski F-Score is 3/9; the balance sheet shows Debt/Equity of 0.12, with cash of $173.7M against debt of $15.8M in FY 2025.

Recent Catalysts & News Wire Analysis

  • Recent coverage: Five news items reference AGL. Headlines include a Yahoo Finance piece on outpacing medical peers, multiple "Buy, Sell, or Hold Post Q2 Earnings?" pieces (TradingView, Yahoo Finance, The Globe and Mail), a GuruFocus item citing a 4.4% gain with a GF Value of $9, and a Simply Wall St piece on revenue and earnings growth.
  • Light signals: Three items are tagged YELLOW (market wire) and two are tagged GREEN (catalyst), per the news wire.
  • Risk watch items: The Q2 earnings reference suggests a recent earnings event; the source does not provide the figures reported.
  • Proprietary signals: Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

  • What drove the FY 2025 operating loss to widen to $-463.2M from $-292.1M in FY 2024, and what is the trajectory into subsequent periods?
  • What are the EPS, P/E, and EV/EBITDA figures, which are absent from the source data and would allow valuation comparison?
  • What were the Q2 earnings results referenced in the news wire, and how did they compare with expectations?
  • Who are the institutional and insider holders, and what is the direction of recent 13F and Form 4 activity?
  • What is the company's revenue mix, customer concentration, and gross margin structure, given a reported gross margin of 0%?

AGL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for agilon health inc. (AGL) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to AGL Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AGL Bull vs. Bear Conversation Board β€” What's Your Call at $84.90?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AGL 🐻 67% BEARISH CONVICTION
1. Pick Your Side on AGL:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $75.63 (-12.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is AGL (D- β€’ RQD 37/100) a Buy at $85.94?

Welcome to the AGL (agilon health inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Misc Health and Biotechnology Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $67.03 (-22.0%)
Spot @ $85.94

Pump the brakes on AGL β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AGL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless agilon health inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $107.43 (+25.0%)
Spot @ $85.94

AGL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AGL, the market is fixating on short-term headline noise in Misc Health and Biotechnology Services and ignoring the balance sheet and cash flow trajectory. At $85.94 (52-wk range $7.48 - $133.04), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%